)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Solid Biosciences
Solid Biosciences (SLDB) investor relations material
Solid Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
SGT-003 Phase 1/2 and Phase 3 trials advanced; 53 INSPIRE DUCHENNE participants had received treatment, and an FDA meeting on preliminary data and a potential accelerated-approval pathway was scheduled for late Q4 2026.
No commercial product revenue to date; losses are expected to continue, with September 30 liquidity projected to fund operations into H1 2028.
Financial highlights
Q3 2026 operating expenses were $57.7M, up 20.0% YoY; net loss was $53.9M versus $45.8M, and loss per share was $0.36 versus $0.48.
9M 2026 operating expenses were $172.3M, up 32.8% YoY; net loss was $165.5M versus $124.5M, and loss per share was $1.23 versus $1.46.
Cash, cash equivalents and available-for-sale securities totaled $348.9M at September 30, 2026, excluding $1.3M restricted cash; no debt was outstanding.
Q3 R&D was $43.6M versus $38.9M and G&A was $14.1M versus $9.2M; increases reflected personnel and SGT-003/SGT-212 manufacturing and clinical or research costs.
Outlook and guidance
Cash and available-for-sale securities were expected to fund operating expenses and capital needs into H1 2028; additional funding will be needed to continue beyond then.
R&D and G&A expenses are expected to rise as trials enroll and advance, manufacturing scales, and pipeline and commercial-readiness work continues.
SGT-212 initial data were anticipated in Q1 2027, subject to enrollment; SGT-501 first dosing was anticipated by year-end 2026, with initial safety data in H1 2027, subject to enrollment.
FDA meeting minutes will inform a subsequent update on SGT-003 regulatory discussions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Solid Biosciences
- Advancing novel gene therapies for DMD and FA, with pivotal FDA meetings and data ahead.SLDB
H.C. Wainwright 28th Annual Global Investment Conference - FDA to review one-year DMD data in Q4; FA and capsid platform progress continue.SLDBCitigroup’s Biopharma Back to School Summit 2026
- Gene therapy programs for DMD and FA show strong progress, with pivotal data and regulatory updates expected soon.SLDB12th Annual Cantor Fitzgerald Global Healthcare Conference
- Net loss rose to $54.8M in Q2 2026 as R&D spending increased; cash runway extends into mid-2028.SLDBQ2 2026
- All proposals passed, including director elections and doubling authorized shares.SLDBAGM 2026
- Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications.SLDBGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead.SLDBJefferies Global Healthcare Conference 2026
- Key clinical progress, $380.7M cash, and a $56.7M net loss with runway into 2028.SLDBQ1 2026
- Key votes include director elections, auditor ratification, and doubling authorized shares.SLDBProxy filing
Next Solid Biosciences earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Solid Biosciences
Next Solid Biosciences earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Solid Biosciences Inc. is a life science company dedicated to developing therapies for neuromuscular and cardiac diseases. The company's primary focus includes advancing a portfolio of gene therapy candidates for various conditions, such as Duchenne muscular dystrophy with its lead product candidate SGT-003, Friedreich's ataxia treated by AVB-202-TT, and BAG3-mediated dilated cardiomyopathy with AVB-401. Solid Biosciences is also working on developing platform technologies that include dual gene expression, allowing for the packaging of multiple transgenes into one vector, and the exploration of novel capsids. The company's mission is driven by a commitment to improve the daily lives of patients living with these debilitating diseases, supported by collaborations and partnerships, including a notable agreement with Ultragenyx Pharmaceutical Inc. for the development and commercialization of new gene therapies for Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts, and its shares are listed on the Nasdaq.